🇺🇸 FDA

Drug profile · INN

erythromycin lactobionate

ERYTHROMYCIN

approved
US status
approved
Patents linked
2
News articles
0

Quick answer

erythromycin lactobionate (ERYTHROMYCIN) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN erythromycin lactobionate
Brand ERYTHROMYCIN
Route INJECTION
Formulation INJECTABLE
Originator Teva Pharma GmbH

Related patents

Search patents →

  1. US 8436154

    Crystallizing method of erythromycin

    Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7129221

    6,11-bicyclic erythromycin derivatives

    Expires Mon Oct 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is erythromycin lactobionate?

erythromycin lactobionate (ERYTHROMYCIN) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for erythromycin lactobionate?

ERYTHROMYCIN is a marketed brand name for erythromycin lactobionate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of erythromycin lactobionate?

erythromycin lactobionate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.